EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Early Initiation of Anti‐TNF Biosimilar in Newly Diagnosed Moderate and Severe Crohn's Disease: Health Economic Insights From the PROFILE Trial

Michal Prokopič

JCC Plus · 2026

DOI: 10.1002/jcc5.70025 ↗
AbstractBibliografische Angaben

Abstract

Plain Language Summary The PROFILE study, published in 2024, compared two ways of treating people newly diagnosed with moderate to severe Crohn's disease. One approach starts highly effective anti‐TNF treatment immediately after diagnosis (‘top‐down’), whereas the other increases treatment step by step only if the disease worsens (‘step‐up’). The study showed that starting effective treatment early leads to better disease control and improved safety. This review focuses on the recently published economic analysis of the PROFILE study. Over a five‐year modelled period, the ‘top‐down’ approach was associated with lower overall healthcare costs, mainly because patients experienced fewer disease flare‐ups, required fewer hospital admissions and underwent fewer intestinal surgeries. Similar cost advantages were observed when lower cost anti‐TNF alternative, adalimumab, was taken into consideration. The reliability of these findings was supported by their consistency across multiple sensitivity analyses. Early anti‐TNF treatment may be particularly important for patients with more aggressive forms of Crohn's disease, as it may help prevent the development of complications. Ongoing follow‐up of the PROFILE study will provide further information on long‐term clinical outcomes and the broader economic impact of this treatment strategy, which in an era of widely available and increasingly affordable biosimilars, will be particularly relevant for healthcare systems and treatment guidelines.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →